Toxin pattern number | Pattern | Percentage of isolates | Resistance category | Distribution among sources | ||||||||||||||
sea | seb | sec | see | seg | ||||||||||||||
MDR (n) | NMDR (n) | Clinical | Non clinical | |||||||||||||||
D.F | W | Bl | U | B | A | Sp | T.S | En | ||||||||||
T1 | + |
|
|
|
| 25% | 7 | 18 | 3 | 5 | 7 | 2 | 1 | 3 | 3 | 1 | 0 | |
T2 |
| + |
|
|
| 9% | 2 | 7 | 1 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 3 | |
T3 |
|
| + |
|
| 2% | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
T4 |
|
|
| + |
| 3% | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
T5 | + | + |
|
|
| 11% | 7 | 4 | 3 | 3 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | |
T6 | + |
| + |
|
| 10% | 4 | 6 | 4 | 3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | |
T7 | + |
|
| + |
| 9% | 3 | 6 | 0 | 1 | 3 | 2 | 2 | 0 | 1 | 0 | 0 | |
T8 |
| + | + |
|
| 2% | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
T9 |
| + |
| + |
| 4% | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | |
T10 |
| + |
|
| + | 2% | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
T11 | + | + | + |
|
| 5% | 1 | 4 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
T12 | + | + |
| + |
| 1% | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
T13 | + | + |
|
| + | 1% | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
T14 | + |
| + | + |
| 1% | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
T15 | + | + | + |
| + | 2% | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | |
T16 | + | + | + | + |
| 1% | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
T17 |
|
|
|
|
| 12% | 3 | 9 | 3 | 1 | 0 | 2 | 1 | 0 | 1 | 2 | 2 |